Rejoindre la communauté AnnuaireRemboursement
EASD 2026 · Milan

28 septembre — 2 octobre 2026 · Milan

EASD 2026.Je vous emmène à Milan.

Cinq jours au cœur du congrès européen du diabète, accréditée presse, avec vos questions dans ma valise. Nouvelles molécules, comprimés, muscle, stabilisation : je vous raconte ce qui est montré, en clair.

Voir le programme Me suivre
  • 28 sept. → 2 oct.2026
  • Allianz MiCoMilan, Italie
  • Le programmejour par jour
  • Replaysjusqu’au 30 octobre

Programme officiel complet

Le programme de l’EASD, jour par jour.

Toutes les sessions de l’EASD 2026, salle par salle : scientifiques, symposiums et laboratoires. Horaires de Milan, les mêmes qu’en France. Ce que je suis au jour le jour, je le raconte dans mon carnet.

Lundi 28 septembre

24 sessions · titres officiels en anglais

Milan
London
Budapest
Dublin
Vienna
Warsaw
Arena
Oslo
Berlin
Madrid
Sofia
  • Session scientifique
  • Laboratoire
  • Symposium satellite
  • Obésité & GLP-1

Faites glisser le planning pour voir toutes les salles. Touchez une session pour son détail.

Lundi 28 septembre

  • 09:00–10:00, Berlin Hall : Diabetes Asia Symposium
  • 09:00–16:30, Milan Hall : Advancing person-centred care across the cardiometabolic spectrum through scientific innovation (Novo Nordisk)
  • 09:00–10:00, Oslo Hall : Diabetes India Symposium
  • 10:00–16:00, London Hall : Changing the course of cardiometabolic disease (Lilly)
  • 10:00–11:30, Madrid Hall : Pushing the limits of what sensing can do for T1D and T2D (Abbott)
  • 10:00–11:00, Sofia Hall : Next-gen diabetes care: the evolving place of basal insulin therapy with technology and AI (Sanofi-Dexcom)
  • 10:30–12:00, Oslo Hall : HSRHE Symposium: Sustainability in Diabetes Care
  • 11:00–12:00, Warsaw Hall : A patient-centered approach to long-term obesity management (Amgen)
  • 11:30–12:30, Sofia Hall : Unlocking scalable T1D autoantibody testing in clinical care (Sanofi)
  • 12:00–13:30, Budapest Hall : Live from the newsroom: obesity uncovered (Regeneron)
  • 12:00–13:00, Dublin Hall : From sensors to integrated care: emerging technologies shaping the future of diabetes (SIBIONICS)
  • 12:30–13:30, Berlin Hall : Making the connections to reduce risk: cardiovascular, renal and metabolic benefits of SGLT2 inhibitors in T2D (Boehringer Ingelheim)
  • 12:30–14:00, Oslo Hall : European Incretin Study Group: Who needs GLP-1? The emerging role of other hormones
  • 13:00–14:00, Madrid Hall : Non-steroidal MRA: expanding cardiorenal care in diabetes and beyond (Sciarc (soutien Bayer))
  • 13:00–14:00, Sofia Hall : A new era in autoimmune T1D: translating emerging potential into clinical reality with teplizumab (Sanofi)
  • 13:00–14:30, Vienna Hall : Rewiring metabolic disease: the role of GLP-1 and glucagon physiology in glucose handling, weight control, CKD and MASH (AstraZeneca)
  • 13:30–15:00, Warsaw Hall : Beyond weight loss: a biology-driven approach to metabolic health (Boehringer Ingelheim)
  • 14:00–14:30, Arena : From headlines to practice: a live podcast on the future of obesity care (Regeneron)
  • 14:30–16:00, Oslo Hall : EDNSG Symposium: Immuno-inflammation and diabetic kidney disease
  • 15:00–19:00, Berlin Hall : INNODIA Symposium: T1D Therapies
  • 15:00–15:30, Dublin Hall : Injection technique in endocrine therapy: lipohypertrophy and outcomes across insulin and GLP-1 injectables (embecta)
  • 15:30–16:30, Madrid Hall : Reducing acute pancreatitis through ApoC-III inhibition in severe hypertriglyceridemia (Sobi)
  • 16:00–17:00, Vienna Hall : Improving heart, kidney and liver health in people with diabetes: a patient-based approach (PeerVoice / EFIM)
  • 16:30–18:00, Oslo Hall : The sixth complication of diabetes: periodontitis

Mardi 29 septembre

  • 08:30–09:00, Milan Hall : Presidential Address
  • 08:30–10:00, Oslo Hall : NEURODIAB Symposium: Treatment of diabetic neuropathy
  • 09:00–09:45, Milan Hall : 58th Claude Bernard Lecture
  • 10:00–11:30, Budapest Hall : OP 4 · The making of MASLD
  • 10:00–11:30, Dublin Hall : OP 5 · From islet failure to regeneration: new strategies in type 2 diabetes
  • 10:00–11:30, London Hall : OP 2 · Novel insulin developments
  • 10:00–11:30, Milan Hall : OP 1 · New approaches of predicting type 2 diabetes
  • 10:00–11:30, Paris Hall : OP 3 · GLP-1 and friends: new clinical insights
  • 10:00–11:00, Spotlight Stage : Early combination vs stepwise therapy: rethinking diabetes treatment
  • 10:00–11:30, Vienna Hall : LBA OP 1 · Transplantation, vaccines and microvascular outcomes
  • 10:00–11:30, Warsaw Hall : OP 6 · Patterns and prevention of cardiovascular diseases
  • 10:30–12:00, Oslo Hall : Tackling vascular challenges related to diabetes by using AI
  • 11:30–12:00, Arena : A commitment to change: integrating environmental responsibility in diabetes care (Sanofi)
  • 11:30–12:00, Spotlight Stage : Fat where we don’t want it: visceral and ectopic fat in type 2 diabetes (Lilly)
  • 12:00–13:00, Vienna Hall : EASD e-Learning expert session: Technology
  • 12:15–13:00, Arena : Lab Talk
  • 12:30–14:00, Oslo Hall : Type 2 diabetes as a systemic disease: from pathophysiology to populations
  • 13:15–14:00, Arena : AI in diabetes 2026: from agentic systems to responsible deployment
  • 13:15–14:15, Vienna Hall : EASD e-Learning expert session: Type 1 diabetes screening
  • 14:15–14:45, Arena : Rethinking diabetes diagnosis targets: how CGM can inform earlier decision making (Dexcom)
  • 14:15–14:45, Spotlight Stage : Making change happen: early-stage T1D pathways (Sanofi)
  • 14:30–16:00, Oslo Hall : Exercise in women with diabetes across the reproductive life course
  • 14:45–16:15, Budapest Hall : OP 10 · Predicting diabetes outcomes with CGM
  • 14:45–16:15, Dublin Hall : OP 11 · Diabetic neuropathy: from risk prediction to novel therapeutic targets
  • 14:45–16:15, London Hall : OP 8 · Diabetes and mental health
  • 14:45–16:15, Milan Hall : OP 7 · Understanding obesity with "omics"
  • 14:45–16:15, Paris Hall : OP 9 · Insulin resistance and diabetes across the lifespan
  • 14:45–16:15, Vienna Hall : LBA OP 2 · New and old drugs: reproductive or metabolic relevance
  • 14:45–16:15, Warsaw Hall : OP 12 · The islet conversation: alpha cells speak and the islet listens
  • 15:00–15:45, Arena : Delphi consensus on disease modification in type 2 diabetes
  • 15:00–15:45, Spotlight Stage : Upper limb complications in diabetes: an under-recognised burden with major functional consequences
  • 16:15–16:45, Arena : One technology, many realities: the real-world value of (predictive) CGM (Roche)
  • 16:15–16:45, Spotlight Stage : Essence of MASH management: practical strategies to improve patient outcomes (Novo Nordisk)
  • 16:30–18:00, Oslo Hall : MASLD Symposium: Metabolism, liver and risk
  • 16:45–17:45, Budapest Hall : Capturing the genetic risk of type 1 diabetes: utility and clinical application
  • 16:45–17:45, Dublin Hall : Disrupted crosstalk between skeletal muscle and other organs in metabolic diseases?
  • 16:45–17:45, London Hall : Metabolically healthy obesity: fact or fiction
  • 16:45–17:45, Milan Hall : 41st Camillo Golgi Lecture
  • 16:45–17:45, Paris Hall : Pancreas plasticity and regeneration
  • 16:45–17:45, Vienna Hall : Joint JACARDI-EUDF Symposium: Reducing the burden of cardiovascular diseases and diabetes in Europe: early evidence from
  • 16:45–17:45, Warsaw Hall : Precision medicine: the next phase?
  • 18:00–18:30, Arena : Early combination therapy in type 2 diabetes: glycemic control and cardiorenal protection (Servier)
  • 18:00–19:00, Berlin Hall : The earlier, the longer, the better in diabetes management (Menarini)
  • 18:00–19:00, Madrid Hall : The early-stage T1D care pathway: practical and real-world experience (Sanofi)
  • 18:00–19:30, Sofia Hall : Semaglutide in obesity care: comprehensive evidence and emerging science (Novo Nordisk)
  • 18:15–19:15, Vienna Hall : The next revolution in diabetes care: from glucose monitoring to dual sensing (Abbott)

Mercredi 30 septembre

  • 07:15–08:15, Madrid Hall : At the cutting edge of automated insulin delivery: CamAPS Liberty, pregnancy and the menstrual cycle (mylife Diabetes Care)
  • 07:15–08:15, Sofia Hall : Metformin for early birds: quick-start strategies to delay diabetes (Merck)
  • 07:45–08:15, Berlin Hall : Did you sleep well? Predictive CGM and nocturnal hypoglycaemia (Roche)
  • 08:30–09:30, Budapest Hall : 20th Albert Renold Lecture
  • 08:30–09:30, Dublin Hall : SURPASS CVOT: clinically relevant trial insights in people living with diabetes and cardiovascular disease
  • 08:30–09:30, London Hall : Disease modifying drug use in type 2 diabetes: barriers and progress
  • 08:30–09:30, Milan Hall : New directions in MASLD: from subtypes to solutions
  • 08:30–09:30, Oslo Hall : Diab IMAGE Symposium: Results from imaging studies in diabetes research
  • 08:30–09:30, Paris Hall : TRIUMPH-2, a Phase 3 clinical trial investigating retatrutide for obesity in patients with type 2 diabetes
  • 08:30–09:30, Vienna Hall : Do sex and gender matter in diabetes and its complications?
  • 08:30–09:30, Warsaw Hall : EASD-ADA joint session: The implementation imperative: closing the gap on diabetes care
  • 09:45–11:15, Budapest Hall : OP 16 · Sharp focus: novel frontiers in diabetic eye disease
  • 09:45–11:15, Dublin Hall : OP 17 · Type 1 diabetes across the lifecourse: incidence, risk and long-term outcomes
  • 09:45–11:15, London Hall : OP 14 · Decoding the molecular response to exercise
  • 09:45–11:15, Milan Hall : OP 13 · Novel agents on the horizon: multi-receptor agonists, GIP antagonism and beta cell immunotherapy
  • 09:45–11:15, Paris Hall : OP 15 · Protecting beta cells: stopping autoimmunity in its tracks
  • 09:45–11:15, Warsaw Hall : OP 18 · Animal models of obesity
  • 10:00–11:30, Oslo Hall : DISG Symposium: Inaugural meeting of the Diabetes Inpatient Study Group
  • 11:15–11:45, Arena : A new era in autoimmune T1D: navigating the realities of teplizumab treatment (Sanofi)
  • 11:15–11:45, Spotlight Stage : From evidence to standard of care: CGM beyond MDI in type 2 diabetes (Abbott)
  • 11:45–12:45, Vienna Hall : EASD e-Learning expert session: Obesity
  • 11:45–13:15, Warsaw Hall : EFSD-NNF Future Leaders Symposium
  • 12:00–12:45, Arena : GLP-1 RAs: equitable health for women across the lifecourse
  • 12:00–13:30, Oslo Hall : Emerging evidence and advances in the management of diabetic foot disease
  • 12:00–12:45, Spotlight Stage : Metabologia Symposium: The emerging cardiovascular–kidney–liver– metabolic (CKLM) interplay: from population health to targeted
  • 13:00–13:45, Arena : Lab Talk
  • 14:00–14:30, Arena : BR1DGE talk: sustainability and cost effectiveness of T1D screening (Sanofi)
  • 14:00–15:30, Oslo Hall : Opportunities for people with diabetes in the EU Safe Hearts Plan
  • 14:00–14:30, Spotlight Stage : Scaling CGM across care in non-insulin treated type 2 diabetes (Dexcom)
  • 14:30–16:00, Budapest Hall : OP 21 · Incretin therapies: from mechanism to the real world
  • 14:30–16:00, Dublin Hall : OP 22 · Diabetic foot: Who is at risk and why?
  • 14:30–16:00, London Hall : OP 20 · Hypoglycaemia beyond glucose numbers
  • 14:30–16:00, Milan Hall : OP 19 · Future obesity treatments in human trials
  • 14:30–16:00, Paris Hall : LBA OP 3 · Islet biology and beta cell function
  • 14:30–16:00, Vienna Hall : OP 24 · Protecting the brain
  • 14:30–16:00, Warsaw Hall : OP 23 · Metabolic health in type 2 diabetes
  • 14:45–15:45, Arena : Post-transplant diabetes: translating SGLT2 inhibitors and GLP-1 receptor agonists into clinical practice
  • 14:45–15:45, Spotlight Stage : AI in medical writing: a panel discussion
  • 16:00–16:30, Arena : A new direction in T1D? Redefining success from survival to freedom (Vertex)
  • 16:00–17:30, Oslo Hall : DESG Symposium: Delivering impact, integrating TPE in practice
  • 16:00–16:30, Spotlight Stage : Early intervention, lasting benefit: reshaping the obesity treatment paradigm (Lilly)
  • 16:30–17:30, Budapest Hall : Amylin in diabetes and obesity - what's new?
  • 16:30–17:30, Dublin Hall : Experimental immunology and islets in type 1 diabetes
  • 16:30–17:30, London Hall : CGM in type 2 diabetes EASD guideline
  • 16:30–17:30, Milan Hall : 12th EASD-NNF Diabetes Prize for Excellence Lecture
  • 16:30–17:30, Paris Hall : Understanding CV risks before type 2 diabetes: well beyond glucose
  • 16:30–17:30, Vienna Hall : Transition consensus working group ADA/EASD/ISPAD: From recommendation to implementation — transition from paediatric to adult care
  • 16:30–17:30, Warsaw Hall : EASD-EASO joint session: Obesity management through different lenses
  • 16:45–17:30, Arena : From postdoc to PI: navigating the path to your independent lab
  • 17:45–18:15, Arena : Muscle health in diabetes: a new lever to improve glycemic control (Abbott)
  • 17:45–18:45, Berlin Hall : Liver-directed approach to moderate to advanced MASH (Madrigal)
  • 17:45–18:45, Madrid Hall : Insulin efsitora alfa in type 2 diabetes: basal insulin from daily to once-weekly (Lilly)
  • 17:45–19:15, Sofia Hall : Advancing the amylin story: from scientific rationale to future cardiometabolic care (Novo Nordisk)

Jeudi 1er octobre

  • 08:30–10:00, Berlin Hall : Diabetes and pregnancy: empowering care through digital innovation
  • 08:30–09:15, Budapest Hall : Orforglipron and the ACHIEVE program: a new oral GLP-1 RA advancing metabolic efficacy and cardiorenal safety in type 2 diabetes
  • 08:30–09:15, Dublin Hall : Human pancreatic islet development
  • 08:30–09:15, London Hall : Challenges in future obesity management
  • 08:30–09:15, Milan Hall : Many paths, one goal: exercise to prevent and treat diabetes
  • 08:30–10:00, Oslo Hall : Implications of hypoglycaemia definitions for clinical trial outcomes
  • 08:30–10:10, Paris Hall : Rising Star Symposium
  • 08:30–09:15, Vienna Hall : Continuous ketone monitoring: a novel technology
  • 08:30–09:15, Warsaw Hall : Cardiovascular autonomic neuropathy
  • 09:30–10:15, Budapest Hall : Results of the SMARTEST trial: Should metformin be replaced by SGLT2 inhibition as first-line treatment in type 2 diabetes?
  • 09:30–10:15, Dublin Hall : Glucagon receptor/ GLP-1 receptor dual agonism in people with obesity and type 2 diabetes: insights from the SYNCHRONIZE Phase 3 studies of
  • 09:30–10:15, London Hall : EASD-EASL joint session: Early approvals, real-world insights, and emerging therapies in MASLD care
  • 09:30–10:15, Milan Hall : Inflammation and type 2 diabetes complications: dogma vs data
  • 09:30–10:15, Spotlight Stage : Spotlight on sphingolipids as risk factors and drivers of diabetes development
  • 09:30–10:15, Vienna Hall : Early-onset type 2 diabetes: the RESET for REMISSION trial and the role of exercise
  • 09:30–10:15, Warsaw Hall : Rewiring beta cell identity: from metabolic failure to therapeutic rescue
  • 10:30–12:00, Berlin Hall : SGGD Symposium: Evolving landscapes in diabetes genetics
  • 10:30–12:00, Oslo Hall : IDF Europe Symposium: the future of diabetes education in the AI era
  • 10:45–12:15, Budapest Hall : OP 27 · From food to function: dietary interventions and metabolic insights
  • 10:45–12:15, Dublin Hall : OP 28 · Beta cell failure begins with stress
  • 10:45–12:15, London Hall : LBA OP 4 · Glycaemic improvements across the diabetes spectrum
  • 10:45–12:15, Milan Hall : OP 25 · The evolving world of automated insulin delivery
  • 10:45–12:15, Paris Hall : OP 26 · Genomic insights across the diabetes types
  • 10:45–12:15, Vienna Hall : OP 30 · Disease modifying drugs and CV outcomes
  • 10:45–12:15, Warsaw Hall : OP 29 · Nine months, many layers: novel dimensions of diabetes in pregnancy
  • 12:15–12:45, Arena : Turn up the volume or fine-tune the balance? Debating GDMT for cardio-kidney protection (Bayer)
  • 12:15–12:45, Spotlight Stage : Let’s talk amylin: the next wave in metabolic and obesity care (Novo Nordisk)
  • 12:30–14:00, Berlin Hall : Matters arising for kidney and diabetes: what’s new from KDIGO
  • 12:30–14:00, Oslo Hall : Transforming diabetes care from the front line
  • 12:45–13:45, Vienna Hall : EASD e-Learning expert session: Organ systems affected by type 2 diabetes
  • 13:00–13:45, Spotlight Stage : EUDF Symposium: How to talk to policymakers? Tips and tricks
  • 14:00–14:45, Arena : Lab Talk
  • 14:00–14:45, Spotlight Stage : CEDA Symposium: The right drug for the right patient
  • 14:00–15:00, Vienna Hall : EASD e-Learning expert session: Hypoglycaemia
  • 14:30–16:00, Berlin Hall : Disordered eating and diabetes: what clinicians need to know
  • 14:30–16:00, Oslo Hall : #dedoc° Symposium: What we wish you knew and why
  • 15:00–15:30, Arena : Strong results, true simplicity: is Omnipod 5 changing the trade-off? (Insulet)
  • 15:00–15:30, Spotlight Stage : Exploring the power of predictive CGM (Roche)
  • 15:30–17:00, Budapest Hall : OP 33 · Biomarkers and prediction of cardiovascular disease
  • 15:30–17:00, Dublin Hall : OP 34 · SGLT inhibitors: from real-world insights to mechanistic and oncological frontiers
  • 15:30–17:00, London Hall : LBA OP 5 · Incretin outcomes and novel biomarker-related insights
  • 15:30–17:00, Milan Hall : OP 31 · Therapeutic rewiring of metabolic liver disease
  • 15:30–17:00, Paris Hall : OP 32 · Diabetic kidney disease: from mechanisms to novel horizons
  • 15:30–17:00, Vienna Hall : OP 36 · Epigenetics and monogenic diabetes
  • 15:30–17:00, Warsaw Hall : OP 35 · Adipocyte biology
  • 15:45–16:45, Arena : Diabetes technologies during hospitalisation
  • 16:30–18:00, Oslo Hall : COGNID Symposium: Cognitive function and diabetes
  • 17:00–17:30, Arena : Reshaping MDI therapy with MiniMed Go (MiniMed)
  • 17:00–17:30, Spotlight Stage : Introducing Libre Duo: a new era in diabetes sensing technology (Abbott)
  • 17:30–18:30, Budapest Hall : Diabetologia Symposium: When diabetes meets the liver: MASLD in focus
  • 17:30–18:30, Dublin Hall : Future of diabetes technology: sensors, algorithms and patients
  • 17:30–18:30, London Hall : What's in your food? Ultra-processed foods and the risk of type 2 diabetes
  • 17:30–17:45, Milan Hall : Induction of Honorary Members 17:45 - 18:30 Milan Hall
  • 17:30–18:30, Paris Hall : Early onset type 2 diabetes and CV outcomes
  • 17:30–18:30, Vienna Hall : Preserving muscle during GLP-1 RA treatment: insights from the trevogrumab COURAGE study
  • 17:30–18:30, Warsaw Hall : The balancing act of energy intake and expenditure to combat diabesity
  • 17:45–18:30, Arena : GIP: neglected not longer
  • 17:45–18:30, Milan Hall : 61st Minkowski Lecture
  • 18:45–20:15, Sofia Hall : Changing the trajectory of chronic metabolic disease: the evolving role of GLP-1-based care (Novo Nordisk)

Vendredi 2 octobre

  • 08:30–09:30, Budapest Hall : EASD-ESC joint session: Advancing cardiovascular protection with incretins and SGLT2 inhibitors
  • 08:30–09:30, Dublin Hall : Human adipose tissue in focus: cellular composition, programming and metabolic risk
  • 08:30–09:30, London Hall : 2nd EASD Diabetes Global Impact Prize Lecture
  • 08:30–09:30, Milan Hall : Please don’t go: adherence and persistence to glucose-lowering medications
  • 08:30–10:00, Oslo Hall : EDEG Symposium: 60 years of EDEG and diabetes prevention
  • 08:30–09:30, Paris Hall : Stem cell-derived islets in clinical trials: towards a cure for type 1 diabetes
  • 08:30–09:30, Vienna Hall : EASD-ERA-ISN joint session: Diabetes and kidneys - clinical challenges and opportunities
  • 08:30–09:30, Warsaw Hall : Microbiome and intestinal permeability-targeted therapies: the next frontier in diabetes treatment
  • 09:30–10:00, Arena : Advancing clinical practice with CGM: evidence, education and system-level implementation (Dexcom)
  • 10:00–11:00, Budapest Hall : OP 40 · What the kidney is telling us: new biomarkers in diabetic nephropathy
  • 10:00–11:00, Dublin Hall : OP 41 · Targeting adipose tissue
  • 10:00–11:00, London Hall : OP 38 · Non cardiovascular complications of diabetes
  • 10:00–11:00, Milan Hall : OP 37 · The icing of the cake in technology
  • 10:00–11:00, Paris Hall : OP 39 · Beta cells on demand: stem cells to beta cell therapy
  • 10:00–11:00, Vienna Hall : LBA OP 6 · Predictors of outcomes and subtypes
  • 10:00–11:00, Warsaw Hall : OP 42 · Brain and diet shaping insulin sensitivity
  • 10:15–10:45, Arena : Lab Talk
  • 10:15–10:45, Spotlight Stage : Is the use of AID effective and safe in older age groups?
  • 10:30–12:00, Oslo Hall : ISG Symposium: Dissecting diabetes by editing of islet cells
  • 11:00–11:30, Arena : Dexcom technology and clinical implications (Dexcom)
  • 11:00–11:30, Spotlight Stage : Facts vs myths in AID therapy (MiniMed)
  • 11:30–12:30, Budapest Hall : OP 46 · Flip the switch: unlocking the beta cell code
  • 11:30–12:30, Dublin Hall : OP 47 · The multiple faces and needs in type 1 diabetes care
  • 11:30–12:30, London Hall : OP 44 · It's all about the brain
  • 11:30–12:30, Milan Hall : OP 43 · Ageing, function and real-world diabetes care
  • 11:30–12:30, Paris Hall : OP 45 · Moving muscle, metabolic medicine
  • 11:30–12:30, Vienna Hall : LBA OP 7 · Incretins: more on signalling, trials and real-world evidence
  • 11:30–12:30, Warsaw Hall : OP 48 · New learnings about old friends: mechanisms and real world use
  • 11:45–12:15, Spotlight Stage : Understanding and preventing weight regain after weight loss
  • 12:30–14:00, Oslo Hall : Current evidence and research priorities for nutrition and GLP-1 medicines
  • 13:00–14:00, Budapest Hall : Time to rethink obesity diagnosis: from BMI to personalised definitions
  • 13:00–14:00, Dublin Hall : The "unpersonal" future of diabetes care: through the eyes of AID and beyond
  • 13:00–14:00, London Hall : ADA/EASD consensus report on management of type 2 diabetes
  • 13:00–14:00, Milan Hall : How complex can it be? New mechanistic insights into diabetic kidney disease
  • 13:00–14:00, Paris Hall : Hormones at work in the brain
  • 13:00–14:00, Vienna Hall : EASD-Breakthrough T1D joint session: Shaping the future of type 1 diabetes care
  • 13:00–14:00, Warsaw Hall : Transcriptional regulation of pancreatic cells

Avant-première, pas résultats en avance : chaque résultat attendra la levée de son embargo. Une communication de congrès n’est ni une publication complète, ni une autorisation, ni un remboursement. Les sessions industrie sont signalées ; y assister ne signifie pas un partenariat. Sources : programme final officiel (PDF) et programme industrie.

Le compte à rebours

Rendez-vous à l’EASD de Milan

Un instant…

Milan

Carnet de voyage · blog et vlog

Mon carnet de Milan

Le congrès jour après jour : mes vidéos, mes coulisses et mes comptes rendus, à lire et regarder ici.

EASD 2026 : J-1 avant Milan pour les nouveautés GLP-1

Les premières pages du carnet arrivent dès lundi 28 septembre, depuis Milan.

Dans 7 jours, je pars seule à Milan
De patiente à accréditée presse : direction l’EASD 2026 !
Mounjaro, Milan, mon parcours… Je vous explique tout !
Toutes mes vidéos sur YouTube

Mon fil rouge

Les six questions que j’emporte

  1. Rétatrutide : qu’attendre de la phase 3 ?Mercredi · 8 h 30
  2. Un GLP-1 en comprimé, qu’est-ce que ça changerait ?Jeudi · 8 h 30
  3. Et après la perte de poids, comment stabiliser ?Mercredi · 14 h 30
  4. Perdre du poids, oui. Mais le muscle ?Jeudi · 17 h 30
  5. Les femmes sont-elles assez prises en compte ?Mercredi · 12 h
  6. Sémaglutide et pancréas : que dit la nouvelle étude ?Vendredi · 11 h 30

Mes réseaux

Me suivre

À lire

Les actus EASD

29 août 2026

À un mois de Milan, vos questions partent avec moi

Le congrès s’ouvre dans un mois. D’ici là, vous pouvez m’envoyer la question que vous aimeriez voir posée aux spécialistes présents à Milan : voici comment ça marche, et ce que je peux réellement en faire.

Ce que je vous ramène, au minimum

Mes engagements depuis Milan

  • Chaque jourUn point sur les informations importantes, puis un débrief le soir : ce que j’ai vu, entendu et compris.
  • En coulissesDes directs et des vidéos courtes depuis le congrès, dès que c’est possible.
  • Vos questionsPosées sur place aux bons interlocuteurs quand l’occasion se présente.
  • Après MilanUn bilan complet, et les sessions rattrapées en replay jusqu’au 30 octobre.
Céline, créatrice de J’assume sous GLP-1

Pourquoi j’y vais

Faire le lien entre la recherche et nos vraies questions.

Je suis Céline, la créatrice de J’assume sous GLP-1. L’EASD est le 62e congrès de l’Association européenne pour l’étude du diabète : pendant cinq jours, chercheurs et spécialistes y présentent leurs travaux. J’y vais pour écouter à la source et vous restituer l’essentiel avec mon regard de patiente.

Mon accréditation presse me permet de couvrir le congrès ; elle ne fait pas de moi une professionnelle de santé.

Mon parcours →Comment je vérifie les informations →Site officiel de l’EASD ↗